Repare Therapeutics Inc. Stock Price, News & Analysis

Repare Therapeutics Inc. (Nasdaq: RPTX) announced participation in two virtual investor conferences in November 2021. The Northland Synthetic Lethality Investor Conference will take place on November 17 at 9:30 a.m. ET, with a live webcast available on the company's website. The Piper Sandler Healthcare Conference is scheduled from November 29 to December 2, with a prerecorded fireside chat available starting November 22 at 10 a.m. ET. Both events will have replays available for 90 days.

Repare Therapeutics (RPTX) presented initial data from its Phase 1/2 TRESR trial at the AACR-NCI-EORTC conference, indicating RP-3500's promising safety and early efficacy in patients with specific genomic alterations. The company raised $101.2 million in a recent follow-on public offering, enhancing its financial position. The Q3 report showed a net loss of $30.9 million, up from $13.8 million year-over-year. R&D expenses increased to $25.4 million due to heightened development activities. Thomas Civik was appointed as the new Chairman of the Board.

Repare Therapeutics Inc. (RPTX) announced the closing of its upsized public offering on November 1, 2021, raising approximately $101.2 million through the sale of 4,600,000 common shares at $22.00 each. The offering included the full exercise of the underwriters' option for an additional 600,000 shares. Major underwriters included Morgan Stanley and Goldman Sachs. This financing positions Repare to further advance its precision oncology initiatives, particularly its clinical candidates, RP-3500 and RP-6306, utilizing its proprietary SNIPRx® platform.

Repare Therapeutics Inc. (RPTX) announced the pricing of a public offering of 4,000,000 common shares at $22.00 each, aiming for total proceeds of $88 million before expenses. The offering is expected to close on November 1, 2021, pending customary conditions. An additional 600,000 shares may be purchased by underwriters within 30 days. This offering is made under a previously filed SEC registration statement. Repare, a precision oncology company, is developing therapies focusing on genomic instability, with notable candidates in various clinical trial phases.

Repare Therapeutics Inc. (NASDAQ: RPTX) has announced a proposed underwritten public offering of $75 million in common shares, with a 30-day underwriters' option for an additional $11.25 million. The offering is subject to market conditions, and the exact terms are yet to be finalized. The shares will be sold by Repare, which has previously filed a registration statement with the SEC. Morgan Stanley, Goldman Sachs, Cowen, and Piper Sandler are acting as joint book-running managers for this offering.

Repare Therapeutics, a precision oncology company, announced participation in a fireside chat at H.C. Wainwright's 2nd Annual Precision Oncology Conference on October 20, 2021, at 12:30 p.m. ET. Investors can access a live webcast via their website, with an archived replay available for 90 days. Repare focuses on synthetic lethality for cancer therapies, utilizing their CRISPR-enabled SNIPRx® platform. Their product pipeline includes RP-3500, an ATR inhibitor in Phase 1/2 development, RP-6306, a PKMYT1 inhibitor in Phase 1, and other early-stage programs.

Repare Therapeutics (RPTX) has presented preliminary Phase 1 clinical data for RP-3500 at the AACR-NCI-EORTC conference, indicating positive early efficacy in patients with solid tumors having specific genomic alterations. Out of 101 patients, the drug showed a favorable safety profile, with only 21.8% experiencing grade 3 anemia and no major adverse events leading to discontinuation. The recommended Phase 2 dose was established at 160mg weekly. Promising antitumor activity was noted, with 49% of patients showing clinical benefit, paving the way for further development of RP-3500.

Repare Therapeutics Inc. (NASDAQ: RPTX) announced an inadvertent early issuance of an abstract by the ANE Conference regarding initial clinical data from its Phase 1/2 trial of RP-3500. The presentation, scheduled for October 8, 2021, will feature significantly more patient data than the abstract. Repare will host a virtual investor webcast on the same day to discuss the updated findings. The company specializes in precision oncology using its SNIPRx® platform to develop targeted cancer therapies, including RP-3500 and others currently in development.

Repare Therapeutics Inc. (RPTX) announced key presentations at the AACR-NCI-EORTC Virtual International Conference on October 8, 2021. Initial data from the ongoing Phase 1/2 trial of RP-3500, an ATR inhibitor targeting advanced solid tumors, will be presented. Dr. Timothy Yap will discuss the biomarker-driven trial results during an oral session, while additional preclinical data will be showcased through a poster presentation. A virtual investor webcast is also scheduled for the same day, allowing insights into the promising trial data.